Posted by Michael Wonder on 21 Jan 2025
Life Molecular Imaging secures FDA fast track designation for [18F] florbetaben in diagnosing cardiac AL and ATTR amyloidosis
21 January 2025 - [18F] florbetaben has been granted a fast track designation for cardiac amyloidosis, which will expedite the development of [18F] florbetaben for this indication.
Life Molecular Imaging announces that the US FDA has granted fast track designation to [18F] florbetaben for the diagnosis of cardiac amyloid light chain and amyloid transthyretin-related amyloidosis.
